文献速递精神分裂症与精神病性障碍

口服与长效抗精神病药治疗早期精神分裂症的头对头随机试验

Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).
PubMed 文献 · Lancet Psychiatry · 2023-01-27

EULAST 是一项在 15 个欧洲国家和以色列 50 家中心开展的开放标签随机试验,纳入 511 例早期精神分裂症患者,比较口服与长效针剂(LAI)抗精神病药的全因停药时间。

要点

  • 早期精神分裂症中,LAI 与口服药的全因停药时间无显著差异。
  • 合并 LAI 组停药比例 64%,合并口服组为 71%,差异未达统计学意义。
  • 研究期间 103 例患者发生 121 次精神科住院,LAI 两组各 1 例死亡。

核心结论

  • 在早期精神分裂症患者中,长效针剂抗精神病药相比口服药在至全因停药时间上无实质优势。

研究设计与样本

  • EULAST 为实用型、随机、开放标签试验,在 15 个欧洲国家和以色列的 50 家综合医院及精神专科门诊开展。
  • 纳入 18 岁以上、DSM-IV 精神分裂症且首次精神病发作距筛选 6 个月至 7 年的患者,按 1:1:1:1 区组随机分配至 LAI 帕利哌酮、LAI 阿立哌唑或相应口服制剂。
  • 随机化按国家和病程(6 个月至 3 年 vs 4 至 7 年)分层,随访至多 19 个月,主要终点为 19 个月内任何原因停药。

主要发现

  • 合并口服药组 247 例中 72 例(29%)完成研究、175 例(71%)符合全因停药标准;合并 LAI 组 264 例中 95 例(36%)完成研究、169 例(64%)符合全因停药标准。
  • 研究期间 103 例患者发生 121 次精神科住院;LAI 两组各 1 例死亡,帕利哌酮组死亡评估为与药物无关,另一例死因未告知研究团队。
  • 350 例有可用数据的参与者中,86 例(25%)曾符合静坐不能标准,70 例(20%)曾符合帕金森综合征标准。

关键数值与推荐

  • 主要终点为 19 个月治疗期间任何原因停药,采用生存分析在 ITT 人群中评估至全因停药时间,并进行了符合方案分析。

临床怎么用

  • 对于早期精神分裂症患者,若临床目标仅为预防抗精神病药停药,没有理由用 LAI 替代口服抗精神病药。
  • LAI 与口服药的选择应结合患者具体情况个体化决策,而非仅基于预防停药的预期优势。

局限性

  • 原文未报告针对开放标签设计、依从性监测或盲法缺失的具体局限性讨论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Schizophrenia is a severe psychiatric disorder with periods of remission and relapse. As discontinuation of antipsychotic medication is the most important reason for relapse, long-term maintenance treatment is key. Whether intramuscular long-acting (depot) antipsychotics are more efficacious than oral medication in preventing medication discontinuation is still unresolved. We aimed to compare time to all-cause discontinuation in patients randomly allocated to long-acting injectable (LAI) versus oral medication. METHODS: EULAST was a pragmatic, randomised, open-label trial conducted at 50 general hospitals and psychiatric specialty clinics in 15 European countries and Israel. Patients aged 18 years and older, with DSM-IV schizophrenia (as confirmed by the Mini International Neuropsychiatric Interview 5 plus) and having experienced their first psychotic episode from 6 months to 7 years before screening, were randomly allocated (1:1:1:1) using block randomisation to LAI paliperidone, LAI aripiprazole, or the respective oral formulations of these antipsychotics. Randomisation was stratified by country and duration of illness (6 months up to 3 years vs 4 to 7 years). Patients were followed up for up to 19 months. The primary endpoint was discontinuation, regardless of the reason, during 19 months of treatment. We used survival analysis to assess the time until all-cause discontinuation in the intention-to-treat (ITT) group, and per protocol analyses were also done. This trial is registered with ClinicalTrials.gov, NCT02146547, and is complete. FINDINGS: Between Feb 24, 2015, and Dec 15, 2018, 533 individuals were recruited and assessed for eligibility. The ITT population included 511 participants, with 171 (33%) women and 340 (67%) men, and a mean age of 30·5 (SD 9·6) years. 410 (80%) of 511 participants were White, 35 (7%) were Black, 20 (4%) were Asian, and 46 (9%) were other ethnicity. In the combined oral antipsychotics treatment group of 247 patients, 72 (29%) patients completed the study and 175 (71%) met all-cause discontinuation criteria. In the combined LAI treatment arm of 264 patients, 95 (36%) completed the study and 169 (64%) met the all-cause discontinuation criteria. Cox regression analyses showed that treatment discontinuation for any cause did not differ between the two combined treatment groups (hazard ration [HR] 1·16, 95% CI 0·94-1·43, p=0·18). No significant difference was found in the time to all-cause discontinuation between the combined oral and combined LAI treatment groups (log rank test χ2=1·87 [df 1]; p=0·17). During the study, 121 psychiatric hospitalisations occurred in 103 patients, and one patient from each of the LAI groups died; the death of the patient assigned to paliperidone was assessed to be unrelated to the medication, but the cause of other patient's death was not shared with the study team. 86 (25%) of 350 participants with available data met akathisia criteria and 70 (20%) met parkinsonism criteria at some point during the study. INTERPRETATION: We found no substantial advantage for LAI antipsychotic treatment over oral treatment regarding time to discontinuation in patients with early-phase schizophrenia, indicating that there is no reason to prescribe LAIs instead of oral antipsychotics if the goal is to prevent discontinuation of antipsychotic medication in daily clinical practice. FUNDING: Lundbeck and Otsuka.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Winter-van Rossum I, Weiser M, Galderisi S, et al. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). Lancet Psychiatry. 2023. PMID: 36716759. doi:10.1016/S2215-0366(23)00005-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。